How retatrutide is different from tirzepatide — and what that means right now

The misconception worth clearing up first

A lot of people come to this question assuming retatrutide is simply a newer, stronger version of Mounjaro, an upgrade you could switch to if you wanted better results. It's an understandable reading of the headlines, and it's not quite right. Retatrutide is a genuinely different compound, developed by Eli Lilly, that adds a third hormonal pathway (the glucagon receptor) to the two already activated by tirzepatide. That structural difference matters scientifically. But the comparison stops there for practical purposes: retatrutide is still in clinical trials, has not been submitted for MHRA approval, and cannot be obtained legally in the UK under any circumstances. Framing it as an available alternative to Mounjaro does people a disservice.

If you have read about retatrutide on social media or seen it described as something UK clinics offer, that is worth treating with real scepticism. The MHRA has warned repeatedly about medicines sold online via unverified channels, and unlicensed experimental compounds carry risks that go well beyond counterfeit pens.

How the two molecules differ at receptor level

Tirzepatide's action on the GIP and GLP-1 receptors is well established. GLP-1 receptor activation slows gastric emptying and increases feelings of fullness; GIP receptor activation appears to amplify that satiety signal and may improve how the body handles glucose. Together they produced average weight reductions of around 20–21% over 72 weeks in the SURMOUNT-1 trial, results which informed NICE's recommendation of tirzepatide (TA1026).

Retatrutide adds glucagon receptor agonism to that picture. Glucagon is primarily known for raising blood sugar, but stimulating the glucagon receptor also appears to increase resting energy expenditure, the rate at which the body burns calories at rest. The hypothesis is that combining all three pathways could produce greater weight loss than either GLP-1 alone or the dual GIP/GLP-1 approach. Phase 2 data published in 2023 reported average weight reductions of roughly 24% at the highest dose over 48 weeks, which is striking, though a 48-week phase 2 study in a few hundred participants is a very different evidence base from the multi-thousand-person phase 3 programme that tirzepatide went through before its MHRA licence. Phase 3 trials are running, but results are not yet available.

Where retatrutide sits in the development timeline

Phase 3 trials are the stage that precedes regulatory submission. Eli Lilly's TRIUMPH programme is testing retatrutide in larger populations over longer periods, including people with obesity and type 2 diabetes, and people with cardiovascular risk. Until those trials report, and until a regulatory dossier is submitted and reviewed, it is not possible to say with any precision when retatrutide might reach UK patients or what its final licensed indications would look like.

For context, the path from promising phase 2 results to a usable prescription medicine typically takes several years. Tirzepatide itself went through a large programme before the MHRA granted its UK licence, and if you are researching it across sources you may find it helpful to read about the different names tirzepatide goes by, since the same molecule appears under several brand and generic terms depending on the context. Anyone telling you retatrutide will be available soon is speculating. If you are curious about how this development story connects to Mounjaro's own journey to the UK market, that context is useful for calibrating expectations.

It is also worth knowing that discussions about switching from tirzepatide to retatrutide (if and when it becomes available) are already a topic of clinical interest. The considerations involved are explored in more detail on our page about moving between these treatments.

What this means for anyone considering treatment today

If you are weighing up weight-management options in the UK right now, the practical answer is that tirzepatide is the licensed dual-agonist medicine available through a private prescription following clinical assessment. Retatrutide is not part of that picture. Mounjaro is available in six strengths, starting at 2.5 mg as a tolerability dose, titrated by a prescriber over time. Its results in clinical trials are well documented, and NICE has formally recommended it for adults meeting specific BMI and comorbidity criteria.

Some readers also ask about the US brand name Zepbound; that is the same molecule as Mounjaro but does not exist as a UK product, if that distinction is relevant to your search, this page explains it clearly. For a broader picture of Mounjaro's evidence base and what private treatment involves, our weight-loss treatment overview covers the detail.

On cost, private tirzepatide treatment pricing has changed significantly since Eli Lilly raised UK list prices in September 2025, the picture varies by dose and provider, and our Mounjaro pricing page sets out what those figures typically look like and what a legitimate price should include. If you have questions our prescribers can address, starting a free consultation is the right next step.